In the era of precision medicine, pathologists are at the forefront of delivery quality care to patients by providing accurate diagnostic, prognostic and predictive information. FDA approval of whole slide imaging (WSI) for primary diagnosis and quantitative image analysis (QIA) of immunohisochemical (IHC) breast biomarkers demonstrate that digital pathology is a proven and essential technology. The targeted audience of this seminar incudes practicing pathologists, residents, fellows, scientists and hospital and laboratory administrators. The distinguished speakers are pathologists and scientists who have many years’ experience using digital pathology (DP) and considered the leaders in this field. The contents include the value of DP, dos and don’ts in the implementation of WSI for primary diagnosis, illustrative cases of how DP empowers pathologists in various practice settings, QIA of IHC breast cancer biomarkers with highlights of new Colleague of American Pathologist (CAP) guideline, and an innovative way of presenting pathology using smart phone or tablet. This seminar will provide practical and informative information to pathologist to enhance the delivery of precision medicine.
What the DPA is doing to advance digital pathology and the Best of Pathology Visions by Dr. Michael Montalto
Digital pathology continues to evolve as vendors arrive, exit, and form new alliances. Hardware platforms have matured but software continues to innovate, with a new focus on image analysis and workflow efficiency. This introductory section will review these changes and set the stage for further advances as pathology doubles down on a future based on pixels. Pathology Visions is the annual scientific meeting of the Digital Pathology Association. This highlight of the best presentations at the most recent as well as past Pathology Visions conferences will focus on the best examples of incorporation of digital pathology into pathology practice to improve diagnostic accuracy and efficiency. Lessons learnt and future opportunities will also be discussed.
A primer on preparing for primary diagnosis using whole slide imaging: The nuts and bolts by Dr. Anil Parwani
Academic Medical Centers across the country are continually under pressure to increase throughput and efficiency while maintaining or improving quality, particularly in the diagnosis of cancer. Whole slide images produced using high throughput robotic scanners have been deployed in many pathology practices for use in intraoperative consultation, 2nd opinion consultations, education, research, image analysis and quality reviews. Only a handful of labs, mostly outside of the USA are using WSI for primary diagnosis. With the approval of the first scanner for primary diagnosis in the USA by the FDA in April 2017, there are many questions around the use of WSI for primary diagnosis. As these devices are adopted in the routine laboratory practice, more and more labs are looking for effective solutions for implementing and validating WSI. In addition to selecting a system as well as validation, labs need to be aware of the necessary quality control parameters that will need to be developed and standardized. This session will discuss practical issues that arise when selecting a WSI system, implementing and validating them for primary diagnosis. Three key aspects will be reviewed in this workshop: selection, implementation and validation of the WSI systems.
Use cases to support community hospital pathologists by Dr. Andrew Evans
Rapid access to subspecialty pathologists is a frequently cited benefit of digital pathology. In addition to reduced turnaround time for consultation on difficult cases, the value proposition of using digital pathology to support community-based general pathologists includes reduced cost by avoiding the need to ship glass slides as well as eliminating the possibility of valuable patient material becoming lost or damaged during transit. Digital consultation also facilitates the rapid referral of cases for which slides, paraffin bocks or wet/frozen tissue need to be sent to a reference center for immunohistochemical and/or molecular work-up that may not be available in the community setting. This presentation will highlight examples of how digital pathology has been used at University Health Network in Toronto, and other centers, to support pathologists based in community hospitals. The fear held by some community pathologists that digital pathology represents a threat to their practice will also be discussed.
The Interpretation and Reporting of Quantitative Image Analysis of Immunohistochemical Biomarkers of Breast Cancer and a New CAP HER2 QIA Guideline by Dr. Marilyn Bui
Breast cancer is common and every breast cancer patient will be subjected to immunohistochemical biomarker testing. This is an area that pathologist can truly enhance the delivery of precision medicine by providing accurate prognostic and predictive information. QIA has shown to improve accuracy, precision and reproducibility of interpretation of IHC breast cancer biomarkers than manual scoring by pathologists. The practical gaps contributing to limited adoption of QIA include not convinced by its value and lack of QIA guideline. This talk will provide practical information of QIA for breast cancer biomarker by IHC using two examples of CAP survey of ER and Her2 with whole slide imaging scored by a FDA approved platform to illustrate its value, the how-to, and how can different practice settings may be benefited. The new CAP QIA guideline of HER2 will also be highlighted.
Interactive Learning: a pedagogical approach using WSI by Dr. Eric Glassy
Education at national meetings such as USCAP usually consist of either PowerPoint presentations or virtual microscopy. The latter uses live video of a glass slide to illustrate key diagnostic features. There is no interactivity with the participants. We will demonstrate a different way to teach using whole slide images and your personal smart phone or tablet.
Marilyn M. Bui, MD, PhD, FCAP
Dr. Bui is certified in Anatomic/Clinical Pathology and Cytopathology by American Board of Pathology. She is the Scientific Director of Analytic Microscopy Core at Moffitt Cancer Center (MCC) and the Director of Cytopathology Fellowship Program at the University of South Florida Morsani College of Medicine. Practicing as an academic pathologist at MCC, a premier cancer center in America and the only NCI/NIH designated comprehensive cancer center in Florida, she has published over 120 peer-reviewed articles, 8 book chapters and 1 book. She has earned national and institutional awards in cancer research and education. Dr. Bui has expertise in digital pathology (DP). Her prior publication and presentation addressed the clinical, teaching and image analysis utility of DP. She is an executive board member of Digital Pathology Association, a member of the College of American Pathologists Digital Pathology Committee and an editorial board member of Journal of Pathology Informatics.
Andrew J. Evans, MD PhD, FCAP, FRCPC
Dr. Andrew Evans is a Staff Pathologist and consultant in Genitourinary Pathology at University Health Network (UHN) in Toronto. He is also an Associate Professor in the Department of Laboratory Medicine and Pathobiology at The University of Toronto. He has served as Director of the UHN Telepathology program since its inception in 2003. UHN has successfully integrated digital pathology into patient care for a variety of applications, including frozen sections, consultation and primary diagnosis. He is currently the Chair of the College of American Pathologists (CAP) Digital Pathology Committee and CAP Pathology and Laboratory Quality Center committees which will revise 2013 guidelines for validating and implementing digital pathology systems for diagnostic purposes.
Eric F. Glassy, MD, FCAP
Dr. Glassy is a community pathologist in Southern California. He shares time between Pathology Inc., a reference laboratory and Affiliated Pathologists Medical Group, a 38 man independent pathology corporation. Dr. Glassy has served as medical director for several laboratories and has won numerous pathology awards, including the Distinguished Service Award and Excellence in Education Award from the College of American Pathologists. He has chaired hospital as well as national committees for the CAP. He served as chairman of the Hematology and Clinical Microscopy Resource, Publications, Curriculum and Digital Pathology Committees of the CAP. He is a past Board Member of the CAP Foundation and a graduate of the Engaged Leadership Academy. He is president of the Digital Pathology Association. He edited, wrote and illustrated several pathology color atlases and developed software programs for pathology reporting, outreach, and practice management. He holds a green belt in Six Sigma.
Michael C. Montalto, PhD
Dr. Montalto is a research and development leader with a broad range of experience at the executive level including R&D, Regulatory, Clinical, Medical and Scientific Affairs. He is currently Executive Director and Head of Immunohistochemistry (IHC) and Pathology Biomarkers at Bristol-Myers Squibb, where he leads histopathology-based assay development for exploratory clinical biomarker and companion diagnostic efforts. Prior to this role, Dr. Montalto was a co-founder of Omnyx L.L.C., a joint venture of GE and University of Pittsburgh Medical Center that commercialized diagnostic pathology imaging and software products. He has patented and published on novel pathology-based multiplex technology (MultiOmyx™;Clarient) for oncology biomarker discovery. He has designed and led global clinical trials for in vitro diagnostic digital pathology devices and served as chair of the regulatory task force of the Digital Pathology Association. He has served as a member of NIH study sections for in vivo cellular imaging centers and currently serves as an officer and executive member of the Digital Pathology Associations (DPA) Board of Directors. Dr. Montalto earned is PhD in cell and molecular biology of cancer from Albany Medical College and received his post-doctoral training in anti-inflammatory drug discovery and whole animal physiology at Brigham and Womens Hospital, Harvard Medical School.
Anil Parwani, MD, PhD, MBA, FCAP
Dr. Anil Parwani is a Professor of Pathology at The Ohio State University. He serves as the Vice Chair and Director of Anatomical Pathology. Dr. Parwani is also the Director of Pathology Informatics and Director of the Digital Pathology Shared Resource at The James Cancer Hospital. His research is focused on diagnostic and prognostic markers in bladder and prostate cancer, and molecular classification of renal cell carcinoma. Dr. Parwani has expertise in the area of Anatomical Pathology Informatics including designing quality assurance tools, bio banking informatics, clinical and research data integration, applications of whole slide imaging, digital imaging, telepathology, image analysis and lab automation. Dr. Parwani has authored over 250 peer-reviewed articles in major scientific journals and several books and book chapters. Dr. Parwani is the Editor-in-chief of Diagnostic Pathology and one of the Editors of the Journal of Pathology Informatics.
This Exhibitor Seminar is not a part of the official USCAP Educational Program at the 2018 Annual Meeting, and is not sponsored by the USCAP. The USCAP does not officially endorse any company or its products and does not award CME credits for attendance at Exhibitor Seminars.